公开(公告)号：US20160178630A1

公开(公告)日：2016-06-23

申请号：US14974889

申请日：2015-12-18

Applicant: Creatv MicroTech, Inc.

Inventor： Daniel L. ADAMS ,  Cha-Mei TANG

IPC: G01N33/574 ,  G01N15/10

CPC classification number: G01N33/57415 ,  G01N15/1456 ,  G01N33/57492 ,  G01N2001/4088 ,  G01N2015/1062 ,  G01N2333/4742 ,  G01N2333/70589

Abstract: Cytokeratin (CK)+/CD45−/DAPI+ cells in the blood of cancer patients have been considered by most as circulating tumor cells (CTCs). Different methods of isolating CTCs results in a wide range of numbers and subgroups of CTCs from same patient. As a result, the clinical significance of the number of CTCs becomes cloudy. Provided herein is methodology to categorize CTCs into morphologically distinct subpopulations, and to use one of the subpopulations in methods for predicting overall survival of a patient having cancer.

Abstract translation: 癌症患者血液中的细胞角蛋白（CK）+ / CD45- / DAPI +细胞被认为是循环肿瘤细胞（CTC）。 分离CTC的不同方法导致来自同一患者的CTC的数量和亚组范围很广。 结果，CTC数量的临床意义变得多云。 本文提供了将CTC分类到形态上不同的亚群的方法，并且在用于预测具有癌症的患者的总体存活的方法中使用一个亚群。

公开(公告)号：US20240345070A1

公开(公告)日：2024-10-17

申请号：US18580301

申请日：2022-07-21

Applicant: Creatv MicroTech, Inc.

Inventor： Daniel L. ADAMS ,  Cha-Mei TANG

IPC: G01N33/50 ,  A61B5/00 ,  G01N33/574 ,  G16H10/40

CPC classification number: G01N33/5091 ,  A61B5/4848 ,  A61B5/7275 ,  G01N33/57492 ,  G16H10/40 ,  G01N2333/70532

Abstract: Means for predicting treatment response in a subject having cancer are disclosed, where the predictions are based comparing the number and size of circulating cancer associated macrophage-like cells (CMLS) and circulating tumor cells (CTCs) found in biological samples at baseline and after induction of therapy, such as blood, from the subject.

公开(公告)号：US20220128544A1

公开(公告)日：2022-04-28

申请号：US17430457

申请日：2020-02-13

Applicant: Creatv MicroTech, Inc.

Inventor： Daniel L. ADAMS ,  Cha-Mei TANG

IPC: G01N33/50 ,  G01N33/574

Abstract: Means for predicting overall survival (OS) and progression free survival (PFS) of subjects having cancer are disclosed, where the predictions are based on the number of CCR5 pools in circulating cells, such as circulating cancer associated macrophage-like cells (CAMLs) and circulating tumor cells (CTCs) found in a biological sample, such as blood, from the subject. CCR5 expression can also be used for companion or complementary diagnostics.